Everolimus – USA

Everolimus – USA

IPR decision: Oct. 05, 2020

AIA Review # Filing Date Institution Date Petitioner Patent Respondent Final Written Decision
IPR2016-01479 07/22/2016 02/15/2017 Par Pharmaceutical, Inc*. 9,006,224 Novartis AG Challenged claims patentable

*This proceeding as initially filed named Par Pharmaceutical, Inc. as the sole Petitioner. Argentum Pharmaceutical LLC was joined as a party to this proceeding via a Motion for Joinder in IPR2017-01063; West-Ward Pharmaceuticals International Limited was joined as a party via a Motion for Joinder in IPR2017-01078. Subsequently, Par and West-Ward separately requested termination of their participation in the proceeding pursuant to settlement. Argentum Pharmaceutical LLC is the sole remaining Petitioner.

US 9,006,224 (Novartis AG; Exp: 07/01/2028)

1. A method for treating pancreatic neuroendocrine tumors, comprising administering to a human subject in need thereof a therapeutically effective amount of 40-O-(2-hydroxyethyl)-rapamycin as a monotherapy and wherein the tumors are advanced tumors after failure of cytotoxic chemotherapy.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved